These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21797685)

  • 21. Appropriate use of the carbapenems.
    Brink AJ; Feldman C; Grolman DC; Muckart D; Pretorius J; Richards GA; Senekal M; Sieling W
    S Afr Med J; 2004 Oct; 94(10 Pt 2):857-61. PubMed ID: 15566108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Infections caused by multiresistant bacteria].
    Zahar JR; Ferroni A
    Rev Prat; 2006 Sep; 56(13):1397-404. PubMed ID: 17002063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections.
    Aguilar-Duran S; Horcajada JP; Sorlí L; Montero M; Salvadó M; Grau S; Gómez J; Knobel H
    J Infect; 2012 May; 64(5):478-83. PubMed ID: 22285591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection.
    Lamoth F; Wenger A; Prod'hom G; Vallet Y; Plüss-Suard C; Bille J; Zanetti G
    Infection; 2010 Aug; 38(4):249-53. PubMed ID: 20552386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of global surveillance in combating bacterial resistance.
    Marchese A; Schito GC
    Drugs; 2001; 61(2):167-73. PubMed ID: 11270935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.
    Thabit AK; Crandon JL; Nicolau DP
    Expert Opin Pharmacother; 2015 Feb; 16(2):159-77. PubMed ID: 25496207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?
    Lode H
    Clin Microbiol Infect; 2005 Oct; 11(10):778-87. PubMed ID: 16153251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of antibiotic-resistant pathogens in the community.
    Yagupsky P
    Pediatr Infect Dis J; 2006 Oct; 25(10):974-6. PubMed ID: 17006309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combating antimicrobial resistance and healthcare-associated infections: the role of the Specialist Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI), 2007-2011. Preface.
    Lord Soulsby of Swaffham Prior
    J Antimicrob Chemother; 2012 Jul; 67 Suppl 1():i1. PubMed ID: 23029664
    [No Abstract]   [Full Text] [Related]  

  • 30. Antibiotic resistance: challenges and successes in respiratory infection.
    Sethi S; Bryan J
    Future Microbiol; 2016; 11(4):481-4. PubMed ID: 27081910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention of health care associated infections and bacterial resistance : guidance for good practice].
    Foguena AK; Cometta A; Senn L
    Rev Med Suisse; 2016 Nov; 12(540):2026-2032. PubMed ID: 28696611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8 year period in a tertiary care hospital in relation to introduction of an infection control programme.
    Gopalakrishnan R; Sureshkumar D
    J Assoc Physicians India; 2010 Dec; 58 Suppl():25-31. PubMed ID: 21563610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections.
    Blondeau JM; Tillotson GS
    Int J Antimicrob Agents; 1999 Jul; 12(2):145-50. PubMed ID: 10418760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial stewardship programs (ASPs): the devil is in the details.
    Cunha CB; Varughese CA; Mylonakis E
    Virulence; 2013 Feb; 4(2):147-9. PubMed ID: 23381468
    [No Abstract]   [Full Text] [Related]  

  • 35. Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010.
    Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S1-3. PubMed ID: 22749052
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
    Goldstein EJ
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii5-6. PubMed ID: 15228047
    [No Abstract]   [Full Text] [Related]  

  • 37. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy.
    Ramsamy Y; Muckart DJ; Han KS
    S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complicated skin and soft tissue infection.
    Dryden MS
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 3():iii35-44. PubMed ID: 20876627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Resistant bacteria in Germany. How great are the dangers?].
    Kresken M
    Kinderkrankenschwester; 2003 Dec; 22(12):532-7. PubMed ID: 16134691
    [No Abstract]   [Full Text] [Related]  

  • 40. Study on antimicrobial susceptibility of bacteria causing neonatal infections: a 12 year study (1987-1998).
    Yu JL; Wu SX; Jia HQ
    Singapore Med J; 2001 Mar; 42(3):107-10. PubMed ID: 11405560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.